EFFECT OF ONE MONTHS TREATMENT WITH PERIPHERALLY ACTING CATECHOL-O-METHYLTRANSFERASE INHIBITOR, ENTACAPONE, ON PHARMACOKINETICS AND MOTOR RESPONSE TO LEVODOPA IN ADVANCED PARKINSONIAN-PATIENTS
Hm. Ruottinen et Uk. Rinne, EFFECT OF ONE MONTHS TREATMENT WITH PERIPHERALLY ACTING CATECHOL-O-METHYLTRANSFERASE INHIBITOR, ENTACAPONE, ON PHARMACOKINETICS AND MOTOR RESPONSE TO LEVODOPA IN ADVANCED PARKINSONIAN-PATIENTS, Clinical neuropharmacology, 19(3), 1996, pp. 222-233
Twelve parkinsonian patients with levodopa-related end-of-dose fluctua
tions in disability were studied in an open-label trial to examine the
effects of peripheral catechol-O-methyltransferase (COMT) inhibition
with entacapone on pharmacokinetics and metabolism of levodopa and on
clinical response to levodopa after a single dose and after 4 weeks' m
edication with entacapone. The clinical response was assessed with con
tinuous monitoring using the motor part of Unified Parkinson's Disease
Rating Scale. Entacapone increased statistically significantly the me
an area under the plasma concentration-time curve (AUC) of levodopa by
29% after a single dose and by 21% after 4 weeks' administration, wit
hout affecting other pharmacokinetic parameters of levodopa, The AUC o
f 3-O-methyldopa decreased by 45% and AUC of homovanillic acid by 21%
after 4 weeks' dosing with entacapone. The duration of motor response
to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%)
after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medica
tion with entacapone. The magnitude of clinical response remained unch
anged, but peak latency of motor response was prolonged after 4 weeks'
medication. The duration and magnitude of dyskinesias also increased.
Peripheral COMT inhibition with entacapone increased significantly th
e bioavailability of levodopa and prolonged its antiparkinsonian effec
t after a single dose and after repeated dosing for 4 weeks. Thus enta
capone seems to be a valuable adjuvant to levodopa treatment in parkin
sonian patients with end-of-dose failure.